# Sarepta Therapeutics, Inc. clinical trials: 52 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 52 trials with Sarepta Therapeutics, Inc. as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Sarepta Therapeutics, Inc.: 52 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sarepta-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 52
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 52, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 21, 2026 | NCT07542314 | Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing... | Sarepta Therapeutics, Inc. | Phase 4 | Recruiting | Duchenne Muscular Dystrophy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07542314) |
| April 17, 2026 | NCT07536061 | A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease | Sarepta Therapeutics, Inc. | Phase 1 | Recruiting | Huntington's Disease | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07536061) |
| May 1, 2025 | NCT06952686 | A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants | Sarepta Therapeutics, Inc. | Phase 3 | Withdrawn | Muscular Dystrophies, Limb-Girdle | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06952686) |
| December 24, 2024 | NCT06747273 | Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy... | Sarepta Therapeutics, Inc. | Phase 1 | Terminated | Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type 2D/R3 | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06747273) |
| September 23, 2024 | NCT06606340 | A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice | Sarepta Therapeutics, Inc. | Observational | Enrolling by invitation | Duchenne Muscular Dystrophy | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06606340) |
| September 19, 2024 | NCT06597656 | A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma... | Sarepta Therapeutics, Inc. | Phase 1 | Terminated | Duchenne Muscular Dystrophy | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06597656) |
| February 21, 2024 | NCT06270719 | An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular... | Sarepta Therapeutics, Inc. | Observational | Enrolling by invitation | Duchenne Muscular Dystrophy | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06270719) |
| February 7, 2024 | NCT06246513 | A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb... | Sarepta Therapeutics, Inc. | Phase 3 | Active not recruiting | Limb-girdle Muscular Dystrophy | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06246513) |
| February 5, 2024 | NCT06241950 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion... | Sarepta Therapeutics, Inc. | Phase 1 | Terminated | Duchenne Muscular Dystrophy | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06241950) |
| November 18, 2023 | NCT06138743 | Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | Sarepta Therapeutics, Inc. | Phase 1/2 | Enrolling by invitation | Myotonic Dystrophy 1 | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06138743) |
| November 15, 2023 | NCT06131983 | Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1 | Sarepta Therapeutics, Inc. | Phase 1/2 | Enrolling by invitation | Muscular Dystrophy, Facioscapulohumeral | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06131983) |
| August 1, 2023 | NCT05967351 | A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study | Sarepta Therapeutics, Inc. | Phase 3 | Enrolling by invitation | Duchenne Muscular Dystrophy | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05967351) |
| June 15, 2023 | NCT05906251 | A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular... | Sarepta Therapeutics, Inc. | Phase 1 | Terminated | Limb Girdle Muscular Dystrophy | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05906251) |
| May 31, 2023 | NCT05881408 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and... | Sarepta Therapeutics, Inc. | Phase 3 | Active not recruiting | Duchenne Muscular Dystrophy | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05881408) |
| May 25, 2023 | NCT05876780 | A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory... | Sarepta Therapeutics, Inc. | Phase 1 | Active not recruiting | Limb Girdle Muscular Dystrophy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05876780) |
| October 27, 2021 | NCT05096221 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne... | Sarepta Therapeutics, Inc. | Phase 3 | Completed | Duchenne Muscular Dystrophy | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05096221) |
| November 12, 2020 | NCT04626674 | A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With... | Sarepta Therapeutics, Inc. | Phase 1 | Recruiting | Duchenne Muscular Dystrophy | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04626674) |
| July 17, 2020 | NCT04475926 | A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in... | Sarepta Therapeutics, Inc. | Observational | Active not recruiting | Limb-girdle Muscular Dystrophy | 205 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04475926) |
| July 1, 2019 | NCT04004065 | Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne... | Sarepta Therapeutics, Inc. | Phase 2 | Terminated | Duchenne Muscular Dystrophy | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04004065) |
| June 20, 2019 | NCT03992430 | A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) | Sarepta Therapeutics, Inc. | Phase 3 | Completed | Muscular Dystrophy, Duchenne | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03992430) |
| June 14, 2019 | NCT03985878 | A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have... | Sarepta Therapeutics, Inc. | Phase 2 | Terminated | Duchenne Muscular Dystrophy | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03985878) |
| December 7, 2018 | NCT03769116 | A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD) | Sarepta Therapeutics, Inc. | Phase 1/2 | Completed | Muscular Dystrophy, Duchenne | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03769116) |
| September 18, 2018 | NCT03675126 | An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen) | Sarepta Therapeutics, Inc. | Phase 1/2 | Terminated | Muscular Dystrophy, Duchenne | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03675126) |
| August 29, 2018 | NCT03652259 | Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E... | Sarepta Therapeutics, Inc. | Phase 1/2 | Terminated | Limb-Girdle Muscular Dystrophy, Type 2E | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03652259) |
| May 22, 2018 | NCT03532542 | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy | Sarepta Therapeutics, Inc. | Phase 3 | Terminated | Duchenne Muscular Dystrophy | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03532542) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 20 |
| Phase 1/2 | 10 |
| Phase 2 | 9 |
| Phase 3 | 9 |
| Phase 4 | 1 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 24 |
| Terminated | 14 |
| Enrolling by invitation | 5 |
| Active not recruiting | 4 |
| Recruiting | 3 |
| Withdrawn | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Muscular Dystrophy, Duchenne | 27 |
| Muscular Dystrophies, Limb-Girdle | 9 |
| Marburg Virus Disease | 2 |
| Coronary Artery Disease | 2 |
| Limb-girdle muscular dystrophy, type 2B | 2 |
| Hemorrhagic Fever, Ebola | 2 |
| Hepatitis C | 2 |
| Sarcoglycanopathies | 2 |
| Muscular Dystrophies | 2 |
| Limb-girdle muscular dystrophy, type 2E | 1 |
| Influenza, Human | 1 |
| West Nile Fever | 1 |
| Encephalitis | 1 |
| Coronary Restenosis | 1 |
| Huntington Disease | 1 |
| Neoplasms | 1 |
| Dysferlinopathy | 1 |
| Myotonic Dystrophy | 1 |
| Cardiovascular Diseases | 1 |
| Muscular Dystrophy, Facioscapulohumeral | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Machinery and tool manufacturers in the United States](https://specstream.ai/data/businesses/machinery-and-tool-manufacturers/united-states)
- [Barbecue restaurants in the United States](https://specstream.ai/data/businesses/barbecue-restaurants/united-states)
- [Oral and maxillofacial surgery practices in the United States](https://specstream.ai/data/businesses/oral-and-maxillofacial-surgery-practices/united-states)
- [Chicken restaurants in the United States](https://specstream.ai/data/businesses/chicken-restaurants/united-states)
- [Printing companies in the United States](https://specstream.ai/data/businesses/printing-companies/united-states)
- [Dialysis clinics in the United States](https://specstream.ai/data/businesses/dialysis-clinics/united-states)
